FIXED COMBINATIONS IN ARTERIAL HYPERTENSION TREATMENT: NOVEL OPPORTUNITIES
https://doi.org/10.15829/1560-4071-2018-5-68-73
Abstract
Arterial hypertension (AH) remains one of the most prevalent cardiovascular disorder in the world, as one of the main risk factors of myocardial infarction and stroke development. Monotherapy of AH is effective in no more than one half of patients even with moderate increase of blood pressure. Combinational antihypertension treatment does influence pathogenetic mechanisms of AH being an optimal solution. It is worthful to apply a fixed combination of telmisartan and hydrochlorothiazide. Such combination provides additional antihypertensive effect with more significant decrease of blood pressure than for the components separately. Also it is protective for organs and tissues that makes it to prescribe such combination to a broad range of patients.
About the Authors
V. I. Podzolkov
ФГАОУ ВО Первый МГМУ им. И. М. Сеченова (Сеченовский Университет)
Russian Federation
Moscow
Russian Federation
Moscow
A. I. Tarzimanova
I. M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ESSERF. Сardiovascular Therapy and Prevention, 2014; 13 (4): 4-14. (In Russ.). DOI:10.15829/1728-8800-2014-4-4-14
2. ESH-ESC Guidelines Committee. 2013 ESH-ESC guidelines for the management of arterial hypertension. J Hypertension 2013; 31: 1281-357. DOI: 101097/01. hjh.0000431740.32696.cc
3. Podzolkov VI. Arterial hypertension. Moscow, Medical information Agency, 2016 (In Russ.) ISBN 978-5-9986-0264-1.
4. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41-6.
5. Williams B, Gosse P, Lowe L, PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24: 193-200.
6. Lacourcire Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19: 104-12.
7. Gosse P, Neutel JM, Schumacher H, et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007; 12: 141-7.
8. Williams B, Lacourcire Y, Schumacher H, et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23 (9): 610-9. DOI: 10.1038/jhh.2009.4
9. Ragot S, Ezzaher A, Meunier A, et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16 (12): 865-73.
10. Instructions for medical use of the drug Telzap LP-003545 (In Russ.)
11. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.
12. Instructions for medical use of the drug Telzap LP-003545, Aprovel LP-001260, Cardosal 20 LSR-000628/10, Edarbi LP-002359, Atacand P N 014373/01, Teveten P N012018/01, Diovan LP-002136 (In Russ.)
13. Instructions for medical use of the drug Telzap plus LP-004359 (In Russ.)
14. McGill JB, Reilly PA. Efficacy and tolerability of a fixed-dose combination of telmisartan plus HCTZ in patients uncontrolled with telmisartan monotherapy. Clinical therapeutics, 2001, 23 (6): 833-85.
15. Neldam S, Edwards C, et al. ATHOS Study Group. Telmisartan plus hydrochlorothiazide compared with amlodipine plus hydrochlorothiazide in older patients with systolic hypertension: Results from a large ABPM study. Am J Geriat Cardiol 2006; 15: 151-60.
16. Sharma AM, Davidson J, Koval S, et al. Telmisartan/hydrochlorothiazide versus valsartan/ hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. 2007; 6: 28.
17. Neutel JM, Littlejohn TW, Chrysant SG, et al. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-tomoderate hypertension. Hypertens Res 2005; 28: 555-63.
18. Fogari R, Zoppi A, Mugellini A, et al. Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Curr Ther Res Clin Exp. 2008 Feb; 69 (1): 1-15. DOI: 101016/j. curtheres.2008.02.003.
19. The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372: 1174-83. DOI: 101016/S01406736(08)61242-8
20. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59. DOI: 10.1056/NEJMoa0801317.
21. Podzolkov VI, Tarzimanova AI. A new generation of blockers receptors of angiotensin. Systemic Hypertension. 2013, 10 (3), 80-85. (In Russ.)
22. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl. 2008 Jun; 1: 32-40.
23. Munger MA. Therapy with blockers of receptors of angiotensin and cardiovascular protection. Modern evidence base and development prospects. Cardiovascular Therapy and Prevention, 2011, 10 (7), 93-104 (In Russ.)
24. Chazova IE, Ratova LG. the First generation of sartans: are there any prospects? Systemic Hypertension, 2010; 4: 5-9. (In Russ.)
Review
For citations:
Podzolkov V.I., Tarzimanova A.I. FIXED COMBINATIONS IN ARTERIAL HYPERTENSION TREATMENT: NOVEL OPPORTUNITIES. Russian Journal of Cardiology. 2018;(5):68-73. (In Russ.) https://doi.org/10.15829/1560-4071-2018-5-68-73
Views:
1982
Email this article 